S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:TRDA

Entrada Therapeutics (TRDA) Stock Price, News & Analysis

$14.17
-0.18 (-1.25%)
(As of 03/28/2024 ET)
Today's Range
$13.67
$14.51
50-Day Range
$11.58
$16.04
52-Week Range
$10.62
$18.44
Volume
105,311 shs
Average Volume
77,956 shs
Market Capitalization
$476.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Entrada Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.2% Upside
$21.00 Price Target
Short Interest
Bearish
10.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of Entrada Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$63,200 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.54) to ($2.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.12 out of 5 stars

Medical Sector

594th out of 938 stocks

Pharmaceutical Preparations Industry

268th out of 423 stocks

TRDA stock logo

About Entrada Therapeutics Stock (NASDAQ:TRDA)

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

TRDA Stock Price History

TRDA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Recap: Entrada Therapeutics Q4 Earnings
See More Headlines
Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRDA
Fax
N/A
Employees
159
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$22.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+48.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-6,680,000.00
Pretax Margin
9.34%

Debt

Sales & Book Value

Annual Sales
$129.01 million
Book Value
$7.26 per share

Miscellaneous

Free Float
31,054,000
Market Cap
$476.11 million
Optionable
Not Optionable
Beta
-0.52
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Dipal Doshi (Age 48)
    CEO & Director
    Comp: $902.08k
  • Mr. Nathan J. Dowden (Age 53)
    President & COO
    Comp: $654.6k
  • Dr. Natarajan Sethuraman Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $654.6k
  • Mr. Kory James Wentworth CPA (Age 44)
    CFO & Treasurer
  • Dr. Jared Cohen J.D.
    Ph.D., General Counsel
  • Ms. Kerry Robert M.S.
    Senior Vice President of People
  • Ms. Karla MacDonald
    Chief Corporate Affairs Officer
  • Mr. Kevin Healy Ph.D.
    Senior Vice President of Regulatory Affairs

TRDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Entrada Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRDA shares.
View TRDA analyst ratings
or view top-rated stocks.

What is Entrada Therapeutics' stock price target for 2024?

2 brokers have issued 12-month price objectives for Entrada Therapeutics' shares. Their TRDA share price targets range from $20.00 to $22.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price.
View analysts price targets for TRDA
or view top-rated stocks among Wall Street analysts.

How have TRDA shares performed in 2024?

Entrada Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, TRDA stock has decreased by 6.1% and is now trading at $14.17.
View the best growth stocks for 2024 here
.

When is Entrada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TRDA earnings forecast
.

How were Entrada Therapeutics' earnings last quarter?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) issued its quarterly earnings results on Monday, March, 6th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.04. Entrada Therapeutics had a negative net margin of 5.18% and a negative trailing twelve-month return on equity of 2.89%.

When did Entrada Therapeutics IPO?

Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share.

Who are Entrada Therapeutics' major shareholders?

Entrada Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (9.02%), Price T Rowe Associates Inc. MD (9.02%), Vanguard Group Inc. (3.19%), Vanguard Group Inc. (3.19%), Wellington Management Group LLP (3.14%) and Northern Trust Corp (0.60%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher and Peter S Kim.
View institutional ownership trends
.

How do I buy shares of Entrada Therapeutics?

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRDA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners